ReNeuron is focused on human retinal progenitor cell therapy (hRPC) for retinitis pigmentosa (RP). Ongoing Phase IIa data show a stable average gain in visual acuity. A nine-patient continuation Phase IIa study is underway at a higher dose. A placing of £15m and an open offer of up to £2.5m at 70p/share, totalling up to £17.5m before costs, are planned to give at least 18 months cash to complete the Phase IIa, potentially initiate a pivotal study in H2 CY22 and progress preclinical exosome and other cell therapy projects. The valuation is adjusted to £190m, formerly £170m.

08 Dec 2020
ReNeuron Group - Funding to complete Phase IIa and other projects


Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
ReNeuron Group - Funding to complete Phase IIa and other projects
ReNeuron Group plc (RENE:LON) | 26.0 0 0.0% | Mkt Cap: 14.8m
- Published:
08 Dec 2020 -
Author:
Dr John Savin -
Pages:
3 -
ReNeuron is focused on human retinal progenitor cell therapy (hRPC) for retinitis pigmentosa (RP). Ongoing Phase IIa data show a stable average gain in visual acuity. A nine-patient continuation Phase IIa study is underway at a higher dose. A placing of £15m and an open offer of up to £2.5m at 70p/share, totalling up to £17.5m before costs, are planned to give at least 18 months cash to complete the Phase IIa, potentially initiate a pivotal study in H2 CY22 and progress preclinical exosome and other cell therapy projects. The valuation is adjusted to £190m, formerly £170m.